vs

Side-by-side financial comparison of Context Therapeutics Inc. (CNTX) and Lakeshore Acquisition III Corp. (LCCC). Click either name above to swap in a different company.

Context Therapeutics Inc. is the larger business by last-quarter revenue ($1.2M vs $717.3K, roughly 1.7× Lakeshore Acquisition III Corp.). Lakeshore Acquisition III Corp. runs the higher net margin — 67.9% vs -1403.9%, a 1471.7% gap on every dollar of revenue.

Context Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing innovative targeted therapies for hormone-driven cancers. Its core pipeline includes candidates for breast, ovarian and other gynecologic malignancies, primarily serving oncology patient populations across North America and Europe.

CNTX vs LCCC — Head-to-Head

Bigger by revenue
CNTX
CNTX
1.7× larger
CNTX
$1.2M
$717.3K
LCCC
Higher net margin
LCCC
LCCC
1471.7% more per $
LCCC
67.9%
-1403.9%
CNTX

Income Statement — Q3 FY2024 vs Q3 FY2025

Metric
CNTX
CNTX
LCCC
LCCC
Revenue
$1.2M
$717.3K
Net Profit
$-17.5M
$486.8K
Gross Margin
Operating Margin
-1503.7%
-32.1%
Net Margin
-1403.9%
67.9%
Revenue YoY
328.2%
Net Profit YoY
-197.2%
EPS (diluted)
$-0.22
$0.08

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CNTX
CNTX
LCCC
LCCC
Q3 25
$717.3K
Q2 25
$467.3K
Q3 24
$1.2M
Q2 24
$840.1K
Q4 23
$224.7K
Q3 23
$290.4K
Q2 23
$293.3K
Q1 23
$355.5K
Net Profit
CNTX
CNTX
LCCC
LCCC
Q3 25
$486.8K
Q2 25
$216.5K
Q3 24
$-17.5M
Q2 24
$-2.3M
Q4 23
$-6.8M
Q3 23
$-5.9M
Q2 23
$-5.0M
Q1 23
$-6.3M
Operating Margin
CNTX
CNTX
LCCC
LCCC
Q3 25
-32.1%
Q2 25
-53.7%
Q3 24
-1503.7%
Q2 24
-367.6%
Q4 23
-3085.3%
Q3 23
-2128.0%
Q2 23
-1804.6%
Q1 23
-1875.0%
Net Margin
CNTX
CNTX
LCCC
LCCC
Q3 25
67.9%
Q2 25
46.3%
Q3 24
-1403.9%
Q2 24
-268.3%
Q4 23
-3012.6%
Q3 23
-2022.7%
Q2 23
-1708.8%
Q1 23
-1774.3%
EPS (diluted)
CNTX
CNTX
LCCC
LCCC
Q3 25
$0.08
Q2 25
$0.06
Q3 24
$-0.22
Q2 24
$-0.04
Q4 23
$-0.42
Q3 23
$-0.37
Q2 23
$-0.31
Q1 23
$-0.40

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CNTX
CNTX
LCCC
LCCC
Cash + ST InvestmentsLiquidity on hand
$84.8M
Total DebtLower is stronger
Stockholders' EquityBook value
$83.9M
$-1.6M
Total Assets
$86.3M
$71.0M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CNTX
CNTX
LCCC
LCCC
Q3 25
Q2 25
Q3 24
$84.8M
Q2 24
$101.5M
Q4 23
$14.4M
Q3 23
$21.7M
Q2 23
$25.1M
Q1 23
$29.8M
Stockholders' Equity
CNTX
CNTX
LCCC
LCCC
Q3 25
$-1.6M
Q2 25
$-1.4M
Q3 24
$83.9M
Q2 24
$101.1M
Q4 23
$11.9M
Q3 23
$18.4M
Q2 23
$24.0M
Q1 23
$28.7M
Total Assets
CNTX
CNTX
LCCC
LCCC
Q3 25
$71.0M
Q2 25
$70.5M
Q3 24
$86.3M
Q2 24
$102.7M
Q4 23
$16.1M
Q3 23
$23.0M
Q2 23
$27.8M
Q1 23
$32.0M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CNTX
CNTX
LCCC
LCCC
Operating Cash FlowLast quarter
$-1.9M
$-206.3K
Free Cash FlowOCF − Capex
$-1.9M
FCF MarginFCF / Revenue
-156.0%
Capex IntensityCapex / Revenue
0.6%
Cash ConversionOCF / Net Profit
-0.42×
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CNTX
CNTX
LCCC
LCCC
Q3 25
$-206.3K
Q2 25
$-218.3K
Q3 24
$-1.9M
Q2 24
$-3.4M
Q4 23
$-7.2M
Q3 23
$-3.5M
Q2 23
$-4.6M
Q1 23
$-5.7M
Free Cash Flow
CNTX
CNTX
LCCC
LCCC
Q3 25
Q2 25
Q3 24
$-1.9M
Q2 24
Q4 23
Q3 23
Q2 23
Q1 23
FCF Margin
CNTX
CNTX
LCCC
LCCC
Q3 25
Q2 25
Q3 24
-156.0%
Q2 24
Q4 23
Q3 23
Q2 23
Q1 23
Capex Intensity
CNTX
CNTX
LCCC
LCCC
Q3 25
Q2 25
Q3 24
0.6%
Q2 24
0.0%
Q4 23
0.0%
Q3 23
0.0%
Q2 23
0.0%
Q1 23
0.0%
Cash Conversion
CNTX
CNTX
LCCC
LCCC
Q3 25
-0.42×
Q2 25
-1.01×
Q3 24
Q2 24
Q4 23
Q3 23
Q2 23
Q1 23

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons